The structure and expression of 14-3-3 s(s) was analysed in squamous carcinomas (SCC) of the vulva and in the vulval pre-malignant lesion vulval intraepithelial neoplasia (VIN). Sequence analysis of the s coding region did not detect mutations in any case of SCC or VIN III and loss of heterozygosity (LOH) occurred in only 2 out of 27 informative cases. In contrast to the absence of genetic change, methylation-speci®c PCR (MSP) analysis revealed dense CpG methylation within the s gene in approximately 60% of cases of vulval SCC, but methylation was not detected in matched, normal epithelial tissue. Methylation was associated in all cases with reduced or absent expression of s mRNA. There was no correlation between s methylation and HPV or p53 status. Analysis of pre-malignant vulval intraepithelial neoplasia (VIN) revealed that s methylation was detectable early in neoplastic development. Coincident methylation, accompanied by loss of expression, of s and p16
The structure and expression of 14-3-3 s(s) was analysed in squamous carcinomas (SCC) of the vulva and in the vulval pre-malignant lesion vulval intraepithelial neoplasia (VIN) . Sequence analysis of the s coding region did not detect mutations in any case of SCC or VIN III and loss of heterozygosity (LOH) occurred in only 2 out of 27 informative cases. In contrast to the absence of genetic change, methylation-speci®c PCR (MSP) analysis revealed dense CpG methylation within the s gene in approximately 60% of cases of vulval SCC, but methylation was not detected in matched, normal epithelial tissue. Methylation was associated in all cases with reduced or absent expression of s mRNA. There was no correlation between s methylation and HPV or p53 status. Analysis of pre-malignant vulval intraepithelial neoplasia (VIN) revealed that s methylation was detectable early in neoplastic development. Coincident methylation, accompanied by loss of expression, of s and p16
INK4a was commonly detected in both SCC and VIN III, suggesting that epigenetic silencing of these two genes is an early and important event in vulval neoplasia.
Introduction
Although vulval SCC is less common than cervical cancer, it is of major mechanistic interest since a proportion of cases contain and express sequences from high-risk HPV types (principally HPV 16), whereas a further, substantial subset of cancers arise via HPV-independent pathways. Pathobiological dierences between HPV positive and HPV negative cancers have been described (Crum, 1992) . HPV positive SCC arise from HPV positive vulval intraepithelial (VIN) (carcinoma in situ) lesions, whereas HPV negative cases arise in association with lichen sclerosis, epithelial hyperplasia and dierentiated VIN (Crum, 1992) . The proportion of VIN which progress to SCC is uncertain. However, clear evidence of the malignant potential of this lesion was aorded in a study which revealed that seven out of eight patients with untreated VIN grade III developed SCC (Jones and Rowan, 1994) . Although allelotype analysis has failed to detect signi®cant dierences in sites of loss of heterozygosity (LOH) between the two forms of the disease (Pinto et al., 1999) , p53 mutation is more common in HPV negative cancers (Lee et al., 1994; Brooks et al., 2000) . Mechanistically, it is hypothesized that mutation in p53 functionally compensates for the absence of HPV 16E6, since this protein mediates inactivation of p53 via promotion of ubiquitin-dependent proteolysis. Despite the more common mutation in p53 in HPV negative cases, a substantial number of vulval SCC occur which lack both mutation and HPV. The mechanism, if any, by which p53 function is compromised in such cases is not known.
s (strati®n) is a member of a large family of highly conserved proteins expressed ubiquitously in human tissues and also present in yeast. s was ®rst identi®ed as a gene expressed speci®cally in strati®ed squamous epithelium (Prasad et al., 1992) . In this study, it was shown that expression of s was absent from a small number of breast carcinoma cell lines, but was not down regulated in other cancer cell lines. s functions in cell cycle checkpoint control and is a critical regulator of senescence in epithelial cells. In studies of human keratinocytes, down-regulation of s allows escape from replicative senescence by forcing cells into the stem cell compartment (Dellambra et al., 2000) . This bypassing of senescence is accompanied by loss of p16 INK4a expression. Primary human keratinocytes transduced by retroviruses expressing anti-sense s become immortalized (Dellambra et al., 2000) . These observations suggest that inactivation of s is equivalent to expression of the E6 and E7 proteins of HPV, since these proteins co-operate to immortalize primary keratinocytes (Hawley-Nelson et al., 1987 (Munro et al., 1999) .
s is induced by p53 in response to DNA damage (Hermeking et al., 1997) . Cells lacking s expression are defective in maintenance of G2 arrest and exhibit increased chromosomal abnormalities even in the presence of functional p53 (Dhar et al., 2000) . The involvement of s in human cancer has been established in studies of breast cancer in which methylationdependent silencing of the gene was observed in a majority of cases of ductal carcinomas (Ferguson et al., 2000) . Further, loss of s occurs early in neoplastic development in breast epithelium (Umbricht et al., 2001 ). Silencing of s expression has also been reported in 43% of primary gastric adenocarcinomas and 89% of hepatocellular carcinomas (Iwata et al., 2000) . To determine whether s inactivation occurs in squamous cell cancers we have analysed the structure and expression of the gene in a series of vulval SCC of varying HPV and p53 status. We show that loss of s, via methylation-dependent transcriptional silencing, occurs commonly in vulval neoplasia, and that it frequently co-exists with silencing of p16
INK4a early in neoplastic development.
Results

Genetic change in s is uncommon in vulval cancers
Using a previously described di-nucleotide repeat (Ferguson et al., 2000) we sought evidence for LOH in the s gene in each of the carcinomas for which matched normal tissue was available. LOH was detected in two out of 27 informative cases analysed. Next we analysed the coding sequence of the gene, but no mutations were detected in the 36 carcinomas analysed. Taken together, these results suggest that genetic change in the s gene is uncommon in vulval SCC.
Frequent hypermethylation of s in vulval cancer
Methylation within the s gene was assessed by MSP employing previously described primers which span CpG dinucleotides 3 to 9 in the s gene (Ferguson et al., 2000) . In total, methylation in s was detected in 19/36 vulval SCC ( Figure 1 , Table 1 ). Methylation of s was not detected in any of the matched normal tissues (Figure 1 ).
Methylation of s is associated with transcriptional silencing
To assess the eect of methylation on expression of s, we performed RT ± PCR of mRNA isolated from matched pairs of normal and tumour tissue ( Figure  2 ). These studies revealed either a marked reduction or a complete absence of expression in all cases available for study in which methylation was detected by MSP. We did not identify a single cancer with methylation in the present series which did not have reduced or absent expression of s.
Silencing of s is an early event in vulval squamous neoplasia
Next we determined whether methylation of s could be detected in a larger series of pre-malignant neoplastic lesions of the vulva. Genomic DNA was isolated from paran-embedded tissue sections from which a precise histopathological diagnosis had been made and reviewed, and used as a substrate for MSP. The samples included four cases of VIN I, six cases of VIN II, and 22 of VIN III. Methylation of s was detected in 0/4 cases of VIN I, 2/6 VIN II and 13/22 VIN III ( Figure 1 and Table 1 ). Taken together, these results show that methylation of s occurs in recognized premalignant vulval lesions and imply that it is an early event in vulval neoplasia.
Silencing of s occurs in SCC positive and negative for HPV
HPV is a recognized aetiological factor in a sub-set of vulval SCC and expression of HPV E6 and E7 cooperatively immortalize primary human genital keratinocytes. We therefore investigated whether there was any relationship between HPV status and methylation of s. HPV 16 DNA sequences were present in 13/36 cancers, in 0/4 VIN I, 1/6 VIN II and 11/22 VIN III (Figure 3 ). Methylation of s was detected in 7/13 of the HPV positive SCC and in 13/23 cases lacking HPV (Table 1) . Of the VIN III with s methylation, HPV DNA sequences were detected in 5/13, whereas 8/13 lacked HPV. These results suggest that epigenetic silencing of s occurs irrespective of HPV status in vulval neoplasia. Figure 1 ). Consistent with methylation analysis, RT ± PCR revealed simultaneous down-regulation of expression in all cases with co-incident methylation ( Figure  2 ). Mutations in p16 INK4a were present in three vulval SCC and there was methylation of s in two of these cases (Table 1 ). In the 13 cases of VIN III with s methylation, we detected simultaneous methylation of p16 INK4a in nine cases.
Methylation of s occurs irrespective of p53 status
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Discussion
In the initial report of the identi®cation of s, it was shown that expression was absent from a small number of breast carcinoma cell lines, but was not down regulated in other cancer cell lines (Prasad et al., 1992) . Subsequently, methylation-dependent transcriptional silencing of s has been demonstrated to occur in a variety of adenocarcinomas. Studies of s expression in squamous carcinomas have been more limited, although down-regulation of s has been reported in a head and neck SCC cell line (Vellucci et al., 1995) . These observations prompted us to examine the structure and expression of s in squamous lesions of the vulva. Initial studies of s in vulval neoplasia revealed a complete absence of mutations in the gene, and a low frequency of LOH. These observations are consistent with studies of breast cancer (Ferguson et al., 2000; Umbricht et al., 2001) and imply that genetic change is, at most, an uncommon mechanism by which s function is compromized in vulval cancers. The ®nding of methylation of s in greater than 50% of cases of vulval cancer parallels reports of adenocarcinomas (Ferguson et al., 2000; Iwata et al., 2000; . The absence of LOH and mutation in s in vulval SCC further emphasises the importance of epigenetic inactivation of the gene in neoplastic development and shows that loss of s occurs in squamous carcinomas in addition to its previously documented loss in adenocarcinomas.
The presence of HPV is associated with vulval SCC and VIN, particularly VIN III (Kagie et al., 1997) . Because s is a recognized target for transcriptional activation by p53, we had originally hypothesized that silencing of s would not occur in HPV positive lesions in which p53 function is abrogated by expression of HPV E6. However, we have observed methylation of s in SCC and VIN III both positive and negative for HPV DNA. In this respect, it is pertinent to note that s was previously reported to be down-regulated in cell lines immortalized by SV40 T (Leers et al., 1993) . 
Methylation-speci®c PCR analysis of s and p16
INK4a in vulval SCC reveals frequent coincident methylation in the two genes. MSP was performed as described in Materials and methods and reaction products resolved on 10% acrylamide gels. Each numbered case (T) refers to the tumour in Table 1 . Reactions for unmethylated (U) and methylated (M) alleles are shown. The upper gel is s and the lower is p16 , the middle panel is expression of s. The lower panel is GAPDH. The samples are run in matched pairs of normal (N) and tumour (T). Cases 1 ± 4 are SCC, cases 5 ± 7 are VIN III. MSP analysis had revealed methylation in both genes in each case. Cases 1 and 2 were mutant for p53. Cases 3, 5 and 6 contained HPV16. Cases 4 and 7 were wild-type for p53 and negative for HPV 16 Figure 3 Detection of HPV 16 in vulval neoplasia. Genomic DNA was ampli®ed with the MY09/MY11 and PCO4/GH20 primer pair as described in Materials and methods, then resolved on 2% agarose gel. M=100 bp molecular weight markers. The lower band is b-globin, the upper band present in lanes 3, 6, 9, 13 and 14 is HPV. Lanes 1 ± 6 are SCC, lanes 7 ± 14 are VIN III. Lane 15 is negative control This observation, taken together with the presence of methylated s in squamous lesions irrespective of HPV status, suggests that inactivation of s and expression of immortalizing oncoproteins from DNA tumour viruses are not mutually exclusive events. SV40 T, like HPV E6, abrogates p53 function thus implying that silencing of s is not restricted to cancers with intact p53. This hypothesis was further con®rmed by the ®nding of s methylation in cancers both mutant and wild-type for p53. It is of course entirely possible that mutation in p53 occurs as a later event in vulval neoplasia, a possibility supported by the absence of mutations in VIN III.
VIN III is a recognized pre-malignant lesion, a proportion of which subsequently develops into SCC. We now show that epigenetic silencing of s occurs in 50% of cases of VIN III and that this is frequently accompanied by simultaneous methylation of p16
INK4a . The common epigenetic inactivation of both genes in a recognized premalignant lesion suggests that these are early changes in malignant development in vulval epithelium. In vitro studies have clearly demonstrated the importance of both s and p16
INK4a in regulating senescence in human keratinocytes. Down-regulation of s expression, which is accompanied by loss of p16
INK4a expression, is sucient to cause immortalization of squamous keratinocytes (Dellambra et al., 2000) . Furthermore, immortalized human keratinocytes show inactivation of p16
INK4a (Munro et al., 1999) . Taken together, these observations imply important roles for both proteins in regulating senescence in human keratinocytes and suggest that loss of s and p16
INK4a might be frequent events in neoplastic transformation in squamous epithelium. The data we now present support this hypothesis, at least in a subset of cases. Despite the recognized invasive potential of VIN III (Jones and Rowan, 1994) , a proportion of cases of VIN III undergo spontaneous regression (Jones and Rowan, 2000) , but molecular genetic determinants of regression or progression have not been established. It will clearly be of interest to determine whether loss of s and/or p16
INK4a expression confers increased risk of malignant progression of high-grade vulval lesions. If this does indeed prove to be the case, immunocytochemical analysis of expression of these proteins in biopsy material may have utility in identifying lesions at high risk of malignant progression. In contrast to SCC and VIN III, methylation in s and p16
INK4a was not detected in VIN I and was infrequent in VIN II. Although the numbers of these lesions analysed was small, these results do suggest that loss of these proteins may be more strongly associated with high-grade squamous lesions. Whether VIN I and VIN II represent immortalized cell populations remains an open question. However, some long-term studies have described persistence and/or recurrence in a signi®cant proportion of such lesions (Basta et al., 1999) . Additional studies of p16
INK4a and s in persistent and recurrent lesions are clearly indicated and would clarify the role of their inactivation in vulval neoplasia.
Materials and methods
Tissues, nucleic acid isolation and HPV typing
Cancers, with patient-matched normal epithelium where available, were obtained at operation. Tissues were snap frozen and stored in liquid N 2 prior to analysis. The presence of a majority of neoplastic tissue was veri®ed in each carcinoma by histopathological analysis of tissue sections. Genomic DNA was isolated by proteinase K digestion, and total RNA by phenol/guanidinium. cDNA was synthesized from 5 mg of total RNA using the Prostar system (Stratagene). In total, 36 SCC, each with patient-matched normal epithelium and six cases of VIN III (also with matched normal) were available for analysis. A second series of vulval SCC and VIN was obtained from the histopathology archive of St Mary's Hospital, Paddington, London. For these cases, the diagnosis of VIN was con®rmed by histopathological examination. Sections containing a majority of neoplastic tissue were then used for preparation of genomic DNA. Fifteen mm sticks were cut, deparanized in xylene, dehydrated in ethanol then subjected to prolonged digestion in proteinase K. To detect HPV DNA in DNA from frozen tissues, co-ampli®cation with the MY09/MY11 and PCO4/GH20 primer pairs was performed (Resnick et al., 1990) . For detection of HPV in DNA from paran sections, each case was initially analysed for the presence of ampli®able DNA using the PCO3/PCO4 primer pair (Greer et al., 1991) . HPV analysis was then performed with the CPI/ CPIIG consensus primer pair which ampli®es a 188 bp product from a wide range of HPV types (Smits et al., 1992) . To determine HPV type, the product of positive ampli®cation with the MY09/MY11 or CPI/CPIIG primers was cleaned with the Qiagen PCR puri®cation kit and directly sequenced.
Analysis of structure and expression of s
Mutation analysis and analysis of LOH were performed using primers and conditions essentially as described by Ferguson et al. (2000) . For analysis of methylation, genomic DNA (1 mg) was modi®ed using the CpG modi®cation system (Intergen) according to the manufacturer's instructions. MSP was done according to Ferguson et al. (2000) with the exception that for DNA isolated from paran sections, PCR was performed for 40 rather than 35 cycles. PCR products were resolved on 10% acrylamide gels and visualized by staining with ethidium bromide. For analysis of expression, cDNA was synthesized as above from RNA isolated from matched pairs of normal and tumour tissue samples. This was used as substrate for PCR with primers as described (Ferguson et al., 2000) . PCR was performed for 28 cycles, under which conditions the reaction is in the exponential phase of ampli®cation. PCR products were resolved on 2% gels, transferred to nylon and then hybridized with an oligonucleotide complementary to the ampli®ed s sequences, end-labelled with g-32 P ATP by polynucleotide kinase.
Analysis of p16 INK4a
The methylation status of p16 INK4a was also studied using MSP. Brie¯y, genomic DNA modi®ed as above was subjected to 35 cycles of PCR (40 cycles for paran-extracted DNA) using primers and conditions described by Herman et al. (1996) . Reaction products were then analysed as above.
Expression of p16
INK4a was assessed by RT ± PCR as described by Gonzalez-Zulueta et al. (1995) .
